CO6640301A2 - Ologo-benzamide compounds and their use - Google Patents
Ologo-benzamide compounds and their useInfo
- Publication number
- CO6640301A2 CO6640301A2 CO12219956A CO12219956A CO6640301A2 CO 6640301 A2 CO6640301 A2 CO 6640301A2 CO 12219956 A CO12219956 A CO 12219956A CO 12219956 A CO12219956 A CO 12219956A CO 6640301 A2 CO6640301 A2 CO 6640301A2
- Authority
- CO
- Colombia
- Prior art keywords
- ologo
- benzamide compounds
- compounds
- benzamide
- tris
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
- C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
- C07C205/06—Compounds containing nitro groups bound to a carbon skeleton having nitro groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
- C07C237/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/08—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
La presente invención incluye compuestos bis y tris-benzamida que bloquean la señalización AR y tienen actividad antineoplásica. También se proporcionan usos para estos compuestos, y composiciones farmacéuticas que los contienenThe present invention includes bis and tris-benzamide compounds that block AR signaling and have antineoplastic activity. Uses are also provided for these compounds, and pharmaceutical compositions containing them.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US34955510P | 2010-05-28 | 2010-05-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6640301A2 true CO6640301A2 (en) | 2013-03-22 |
Family
ID=45004429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO12219956A CO6640301A2 (en) | 2010-05-28 | 2012-12-04 | Ologo-benzamide compounds and their use |
Country Status (14)
Country | Link |
---|---|
US (3) | US20130231385A1 (en) |
EP (1) | EP2575453B1 (en) |
JP (3) | JP2013528174A (en) |
KR (1) | KR20130115108A (en) |
CN (1) | CN102958364A (en) |
AU (1) | AU2011258009B2 (en) |
BR (1) | BR112012030298A2 (en) |
CA (1) | CA2800811C (en) |
CL (1) | CL2012003322A1 (en) |
CO (1) | CO6640301A2 (en) |
EA (1) | EA201291460A1 (en) |
MX (1) | MX2012013855A (en) |
SG (1) | SG186076A1 (en) |
WO (1) | WO2011150360A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130231385A1 (en) | 2010-05-28 | 2013-09-05 | The Board Of Regents Of The University Of Texas Systems | Oligo-benzamide compounds and their use |
WO2012177624A2 (en) * | 2011-06-21 | 2012-12-27 | The Johns Hopkins University | Focused radiation for augmenting immune-based therapies against neoplasms |
US8835493B2 (en) | 2011-11-23 | 2014-09-16 | Board Of Regents, The University Of Texas System | Oligo-benzamide compounds for use in treating cancers |
US8754124B2 (en) | 2011-11-23 | 2014-06-17 | Board Of Regents, The University Of Texas System | Oligo-benzamide compounds and their use in treating cancers |
CN107312039B (en) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | A kind of preparation method of tenofovir prodrug |
RU2743206C2 (en) * | 2015-05-18 | 2021-02-16 | Кэнди Терапьютикс Лимитед | Double neurokinin-1/neurokinin-3 receptor antagonists for treating sex hormone dependent diseases |
AU2016323425B2 (en) | 2015-09-15 | 2020-10-22 | Savage Medical, Inc. | Devices and methods for anchoring a sheath in a tissue cavity |
USD874674S1 (en) * | 2016-10-17 | 2020-02-04 | Brandcore Limited | Vibrator |
KR20210100115A (en) * | 2018-12-03 | 2021-08-13 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Oligo-benzamide analogs and their use in the treatment of cancer |
WO2023154856A1 (en) * | 2022-02-11 | 2023-08-17 | Board Of Regents, The University Of Texas System | Oligo-benzamide analogs and their use in cancer treatment |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1903899A (en) | 1933-04-18 | Cabboxylic acid abylides oe the benzene sebies and process oe making | ||
US3951914A (en) | 1974-07-30 | 1976-04-20 | E. I. Du Pont De Nemours And Company | Process for preparing poly(1,4-benzamide) in cyclic sulfone media |
US5212203A (en) | 1986-01-21 | 1993-05-18 | Centre International De Recherches Dermatogologiques (C.I.R.D.) | Aromatic benzamido compounds; their preparation and their use in human or veterinary medicine or in cosmetic preparations |
US5734081A (en) | 1994-08-05 | 1998-03-31 | Warner-Lambert Company | Arylthio compounds |
WO2001064642A2 (en) | 2000-02-29 | 2001-09-07 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
US7355081B2 (en) * | 2002-04-17 | 2008-04-08 | The University Of North Carolina At Chapel Hill | Curcumin analogues and uses thereof |
EP1670483A4 (en) | 2003-09-10 | 2010-02-17 | Merck & Co Inc | 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators |
EP1718323B1 (en) | 2004-02-20 | 2011-12-07 | The Trustees of The University of Pennsylvania | Binding peptidomimetics and uses of the same |
WO2006086345A2 (en) | 2005-02-07 | 2006-08-17 | The Trustees Of Columbia University In The City Of New York | Methods to treat or prevent hormone-resistant prostate cancer using sirna specific for protocadherin-pc, or other inhibitors of protocadherin-pc expression or activity |
JP5536336B2 (en) | 2005-11-08 | 2014-07-02 | チョンウェ ファーマ コーポレイション | Methods for the treatment of α-helix analogs and cancer stem cells |
US8236983B2 (en) | 2008-03-13 | 2012-08-07 | Board Of Regents, The University Of Texas System | Composition and method for the treatment of diseases affected by apoptosis |
WO2008112941A1 (en) * | 2007-03-13 | 2008-09-18 | Board Of Regents The University Of Texas System | Composition and method for the treatment of diseases affected by a peptide receptor |
JP5535925B2 (en) * | 2007-10-26 | 2014-07-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Diarylhydantoin compounds as androgen receptor modulators |
DE112009000300T5 (en) | 2008-02-08 | 2011-01-20 | Aileron Therapeutics, Inc., Cambridge | Therapeutic Peptidomimetic Macrocycles |
BRPI0907844B8 (en) * | 2008-02-22 | 2021-05-25 | Radius Health Inc | compounds and method for modulating an androgen receptor, preparation processes and pharmaceutical composition thereof and their uses |
US8188098B2 (en) | 2008-05-19 | 2012-05-29 | Hoffmann-La Roche Inc. | GPR119 receptor agonists |
CN101643451B (en) * | 2008-08-07 | 2013-03-06 | 浙江海正药业股份有限公司 | Peroxisome proliferator-activated receptor subtype delta agonist compound and preparation method thereof |
PL2352508T3 (en) | 2008-10-17 | 2014-09-30 | Dana Farber Cancer Inst Inc | Muc-1 cytoplasmic domain peptides as inhibitors of cancer |
WO2010088498A1 (en) | 2009-01-30 | 2010-08-05 | Bayer Healthcare Llc | Methods for treating estrogen receptor positive cancer by x-box binding protein 1 inhibition |
BR112012009262A2 (en) | 2009-10-23 | 2019-09-24 | Health Research Inc | A method for inhibiting the proliferation of air-positive cancer cells in an individual diagnosed with or suspected to have air-positive cancer and a method for identifying whether an individual is a candidate for treatment with a composition. |
US20130231385A1 (en) | 2010-05-28 | 2013-09-05 | The Board Of Regents Of The University Of Texas Systems | Oligo-benzamide compounds and their use |
US8754124B2 (en) * | 2011-11-23 | 2014-06-17 | Board Of Regents, The University Of Texas System | Oligo-benzamide compounds and their use in treating cancers |
US8835493B2 (en) * | 2011-11-23 | 2014-09-16 | Board Of Regents, The University Of Texas System | Oligo-benzamide compounds for use in treating cancers |
-
2011
- 2011-05-27 US US13/700,500 patent/US20130231385A1/en not_active Abandoned
- 2011-05-27 CN CN2011800323958A patent/CN102958364A/en active Pending
- 2011-05-27 AU AU2011258009A patent/AU2011258009B2/en active Active
- 2011-05-27 EP EP11787517.9A patent/EP2575453B1/en active Active
- 2011-05-27 BR BR112012030298A patent/BR112012030298A2/en not_active IP Right Cessation
- 2011-05-27 EA EA201291460A patent/EA201291460A1/en unknown
- 2011-05-27 MX MX2012013855A patent/MX2012013855A/en not_active Application Discontinuation
- 2011-05-27 KR KR1020127033981A patent/KR20130115108A/en not_active Application Discontinuation
- 2011-05-27 WO PCT/US2011/038395 patent/WO2011150360A1/en active Application Filing
- 2011-05-27 SG SG2012087235A patent/SG186076A1/en unknown
- 2011-05-27 JP JP2013512048A patent/JP2013528174A/en active Pending
- 2011-05-27 CA CA2800811A patent/CA2800811C/en active Active
-
2012
- 2012-11-27 CL CL2012003322A patent/CL2012003322A1/en unknown
- 2012-12-04 CO CO12219956A patent/CO6640301A2/en not_active Application Discontinuation
-
2015
- 2015-11-04 US US14/932,480 patent/US9856206B2/en active Active
-
2016
- 2016-06-21 JP JP2016122278A patent/JP6385986B2/en active Active
-
2018
- 2018-01-02 US US15/860,095 patent/US10618869B2/en active Active
- 2018-05-22 JP JP2018097720A patent/JP2018131459A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112012030298A2 (en) | 2015-09-29 |
JP2013528174A (en) | 2013-07-08 |
EP2575453B1 (en) | 2018-08-01 |
JP2018131459A (en) | 2018-08-23 |
JP2017019769A (en) | 2017-01-26 |
KR20130115108A (en) | 2013-10-21 |
CN102958364A (en) | 2013-03-06 |
CA2800811A1 (en) | 2011-12-01 |
US10618869B2 (en) | 2020-04-14 |
US20180230087A1 (en) | 2018-08-16 |
US20130231385A1 (en) | 2013-09-05 |
US20160130217A1 (en) | 2016-05-12 |
JP6385986B2 (en) | 2018-09-05 |
SG186076A1 (en) | 2013-01-30 |
AU2011258009B2 (en) | 2016-04-21 |
MX2012013855A (en) | 2013-04-08 |
EP2575453A4 (en) | 2015-12-23 |
AU2011258009A1 (en) | 2013-01-10 |
US9856206B2 (en) | 2018-01-02 |
WO2011150360A1 (en) | 2011-12-01 |
CA2800811C (en) | 2019-02-26 |
EA201291460A1 (en) | 2013-11-29 |
CL2012003322A1 (en) | 2014-03-28 |
EP2575453A1 (en) | 2013-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6640301A2 (en) | Ologo-benzamide compounds and their use | |
CL2016001287A1 (en) | Substituted benzamides and procedure for use | |
GT201700189A (en) | DERIVATIVES OF USEFUL REPLACED NUCLEOSIDS AS ANTINEOPLASTIC AGENTS | |
CO7121325A2 (en) | New diazaespirocicloalcanos and azaespirocicloalcanos | |
CO6321189A2 (en) | BENCEN-SULFONAMIDE TIAZOL AND OXAZOL COMPOUNDS | |
NI201500167A (en) | CHEMICAL COMPOUNDS | |
SV2018005794A (en) | USEFUL REPLACED CARBONUCLEOSIDE DERIVATIVES AS ANTHINEOPLASTIC AGENTS | |
GT201400297A (en) | NEW TIENOPIRIMIDINE DERIVATIVES, A PROCESS FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
ECSP11011390A (en) | ESPIRO-AMIDAS SUBSTITUTED COMPOUNDS | |
UY34632A (en) | OXAZOLIDIN- 2- ONA COMPOUNDS AND USES OF THE SAME | |
GT201400230A (en) | NEEDS OF URACILO SPYROOXETHANE | |
CL2012003415A1 (en) | Compounds derived from 2-oxo-piperidine and 1,1-dioxide-thiazine, mdm2 inhibitors; pharmaceutical composition that includes them; and its use for the treatment of cancer. | |
UY34220A (en) | INDAZOLS, PHARMACEUTICAL COMPOSITIONS AND USE OF THE SAME | |
CL2012002189A1 (en) | Compounds derived from substituted pyrrolidine-2-carboxamides; mdm2-p53 interaction inhibitors; pharmaceutical composition; and its use for the treatment of cancer, particularly solid tumors. | |
GT201200165A (en) | TRIAZOLOPIRIDINS | |
CO2018002211A2 (en) | Pyridinone dicarboxamide for use as bromodomain inhibitors | |
CR9786A (en) | BENCIMIDAZOL-THIOPHEN COMPOUNDS | |
NI201500096A (en) | CHEMICAL COMPOUNDS | |
CO6410315A2 (en) | NEW ANTI-ALFA5BETA1 ANTIBODIES AND THEIR USES | |
ECSP17069696A (en) | NOVEL COMPOUNDS | |
AR125920A2 (en) | COMPOSITIONS COMPRISING VORTIOXETINE AND DONEPEZIL | |
UY32520A (en) | COMPOUNDS THAT HAVE AGONIST ACTIVITY OF THE GLUCOCORTICOESTEROID RECEPTOR | |
DOP2018000066A (en) | USEFUL COMPOUNDS TO INHIBIT ROR-GAMMA-T | |
ECSP13012679A (en) | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE ALISPORIVIR | |
GT201300225A (en) | TIENO (2,3-D) DERIVED FROM PIRIMIDINE AND ITS USE FOR THE TREATMENT OF ARRITMIA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |